型号:
产品价格:电议      采购度:1611      原产地:美洲
发布时间:2021/7/24 4:23:02 所属地区:上海 上海市
简要描述:
Palbociclib (PD 0332991) monohydrochloride 是高选择性的 CDK4/6 抑制剂,IC50 分别为 11 nM 和 16 nM。Palbociclib monohydrochloride 有潜力用于 ER 阳性和 HER2 阴性乳腺癌的研究。
产品详情
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 827022-32-2
MCE 站:Palbociclib monohydrochloride
产品活性:Palbociclib (PD 0332991) monohydrochloride 是高选择性的 CDK4/6 抑制剂,IC50 分别为 11 nM 和 16 nM。Palbociclib monohydrochloride 有潜力用于 ER 阳性和 HER2 阴性乳腺癌的研究。
作用靶点:CDK
In Vitro: The IC50 of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser780 in MDA-MB-435 breast carcinoma cells is 66 nM. Palbociclib is equally effective at reducing Rb phosphorylation at Ser795 in this tumor with an IC50 of 63 nM, and similar effects on both Ser780 and Ser795 phosphorylation are obtained in the Colo-205 colon carcinoma. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectively inhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC50s are 0.01 ?M, 0.01 ?M, 0.06 ?M, and 0.6 ?M, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC50>10 ?M). The flow cytometry results show that Palbociclib at concentrations between 0 to 1.0 ?M induces G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdU incorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation (indicating G1 arrest) in the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at a concentration of 0.05 ?M, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05).
In Vivo: Palbociclib (PD 0332991) monohydrochloride exhibits significant antitumor efficacy against multiple human tumor xenograft models. In mice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150 or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of ~50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise, robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis is apparent at 150 mg/kg and some cell kill is evident at the highest dose.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Kinase Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | CNS-Penetrant Compound Library | Peptidomimetic Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Ro-3306 | Seliciclib | Flavopiridol | NVP-2 | SNS-032 | AZD-5438 | Kenpaullone | GSK 3 Inhibitor IX | AUZ 454 | XL413 hydrochloride | CGP60474 | Wogonin | CVT-313 | NG 52 | BMS-265246 | (R)-CR8 trihydrochloride | R547 | PHA-767491 hydrochloride | CDK12-IN-3 | KH-CB19 | CDK2-IN-4 | Purvalanol A | Cucurbitacin E | THZ1-R | FMF-04-159-2 | LY2857785 | CP-10 | ML167
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
更新时间:2024/1/2 10:14:41
留言咨询
温馨提示
1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。
相关新闻
相关产品